Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Impact of genomics in the future of ALL treatment

Anthony Moorman • 8 Jun 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia

Anthony Moorman, PhD, Newcastle University, Newcastle, UK, discusses how genomics research could impact the future direction of acute lymphoblastic leukemia (ALL) treatment, in particular talking on the benefits of risk stratification based on molecular subtypes to optimise treatment. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Anthony Moorman

5:23
Redefining low risk high hyperdiploidy in pediatric ALL
Anthony Moorman • 8 Jun 2021
4:31
T-ALL diagnosis: cytogenetics, genomics and risk assessment
Anthony Moorman • 8 Jun 2021
3:02
Enhanced risk stratification in pediatric ALL
Anthony Moorman • 10 Nov 2020
5:10
Prognostic factors in adult ALL patients
Anthony Moorman • 10 Nov 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals